Study of Tarceva and Targretin in Stage I-II Lung Cancer
The purpose of this study is to learn the effects on lung cancer of 2 new drugs, Tarceva and Targretin, given in combination before surgical removal of the tumor. Tarceva is approved by the Food and Drug Administration (FDA) for lung cancer. Targretin is approved for the treatment of cutaneous T-cell lymphoma. This combination of drugs is experimental.
Checked against the public recordLast updated Jan 8, 2019 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Dartmouth-Hitchcock Medical Center
- Interventions being studied
- Drug: erlotinib (Tarceva) and bexarotene (Targretin)
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Resectable stage I or II non-small-cell lung cancer * Prior tissue biopsy (not cytology) available for research analysis * Adequate hepatic and renal function Exclusion Criteria: * Prior chemotherapy or radiotherapy
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Norris Cotton Cancer CenterLebanon, New Hampshire
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 8, 2019. Always confirm current availability with the study team.